Integrating Clinical Pharmacists Into Collaborative Care For Patients With T2D To Realize Early Benefits of Once-Weekly Insulin Regimens

ActionED

The management of type 2 diabetes (T2D) is complex, requiring a multidisciplinary, patient-centered approach that accounts for individualized glycemic and weight goals, comorbidities, hypoglycemia risk, medication costs, and individual preferences. Therapeutic inertia and patient reluctance often delay insulin initiation and intensification in patients with persistent hyperglycemia despite multiple antihyperglycemic agents. The emergence of once-weekly basal insulin analogues represent a transformative advancement in T2D management, offering a simplified treatment paradigm to address common barriers to insulin initiation and adherence.

The novel pharmacokinetics, distinct initiation and titration protocols, and unique patient counseling requirements for once-weekly formulations present new educational challenges for the multidisciplinary diabetes care team. Clinical pharmacists integrated within the collaborative care team are well-positioned to counsel patients on medication use, identify cost-saving opportunities, and educate on proper insulin administration techniques.

To support translation and implementation of the latest evidence into routine clinical practice, this program provides pharmacists with a personalized learning experience. Pharmacists complete an initial assessment, receive individualized recommendations for education, and access tools and resources to develop their own action plan for keeping pace with the latest guidance and evidence to mitigate therapeutic inertia, individualize treatment, and optimize patient engagement when transitioning a T2D patient to a weekly basal insulin treatment plan.

Faculty: Athena Philis-Tsimikas, MD, Kevin Cowart, PharmD, MPH, BCACP, CDCES, Jennifer Trujillo, PharmD

Release Date: May 29, 2026

Expiration Date: May 29, 2027